首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1623510

免疫測定市場規模依產品、技術、樣本、應用、最終用戶、地區、範圍和預測劃分

Immunoassay Market Size By Product, By Technology (ELISA, Chemiluminescence Immunoassay, Immunofluorescence Assay, Rapid Tests, ELISpot, Western Blotting), By Specimen, By Application, By End-User, By Geographic Scope And Forecast

出版日期: 2024年11月01日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

免疫測定市場規模及預測

2023 年免疫測定市場規模價值 275.3 億美元，預計到 2031 年將達到 396.6 億美元，2024 年至 2031 年的複合年增長率為 4.67%。免疫測定是一種實驗室技術，透過分析物質（通常是蛋白質或其他生物分子）與特定抗體的相互作用來檢測其存在或數量。簡而言之，抗體用於識別和結合目標分子，從而可以識別或量化該分子。免疫測定廣泛應用於醫學、生物學、環境科學和食品安全等許多不同領域。在醫學上，它們通常用於診斷感染、監測荷爾蒙水平、識別體內的藥物和毒素以及測試對疫苗的免疫反應。

此外，它們還用於農業領域以識別食品中的毒素，以及用於環境監測以量化水和土壤中的污染物。

全球免疫測定市場動態

影響免疫測定市場的關鍵市場動態

主要市場驅動因子

慢性病的增加：

癌症、糖尿病和心血管疾病等慢性病在全球範圍內的流行率不斷上升，需要早期發現和監測，從而推動了臨床環境中對免疫測定的需求，以提供準確、快速的檢測。。

技術進步：

免疫測定技術的不斷發展，包括自動化和高通量系統，正在提高測試的效率、靈敏度和特異性。這些技術進步使得疾病識別和監測得到改善，從而推動了免疫測定市場的擴張。

對即時診斷偵測的需求不斷增加：

對於在護理點（例如診所或家庭護理）環境中進行快速、可靠且易於使用的診斷測試的需求日益增加。能夠快速提供結果的免疫測定法正成為這些環境中不可或缺的工具，並且正在擴大其市場。

擴大藥物開發和治療的應用：

免疫測定在藥物開發和治療中得到越來越多的應用，以輔助藥物發現、藥物動力學和毒理學研究。這些產業對研發的投入不斷增加，正在推動免疫測定的需求並加速市場發展。

主要問題

先進免疫測定系統成本高：

先進免疫測定技術的開發和應用成本很高。其中包括昂貴的設備和試劑成本，這成為中小型實驗室和醫療機構採用這些技術的主要障礙，限制了市場擴張。

專業技能人才短缺：

複雜的免疫測定方法必須由具有高水平專業知識的人員執行和解釋。缺乏訓練有素的人力阻礙了免疫測定技術的有效使用和接受，尤其是在新興地區，從而阻礙了市場擴張。

主要趨勢：

整合人工智慧（AI）與機器學習（ML）：

人工智慧和機器學習正在迅速融入免疫測定平台，以改善數據處理和解釋。這種整合可以提高診斷準確性、預測分析能力並簡化實驗室程序，突破標準免疫測定應用的界限。

即時診斷（POC）與居家檢測：

設計緊湊、易於使用的免疫測定測試以用於即時診斷（POC）和家庭測試的趨勢日益增長。這種轉變是由對更快、更方便的測試選項的需求所推動的，這些選項可以提供即時的結果，從而減少對專門測試實驗室的需求。

多重偵測：

多路復用方法可以同時測試多種分析物，正變得越來越流行。這種趨勢越來越受歡迎，因為對高通量和高效測試程序的需求很高，這些程序可以節省時間和成本，同時從單一樣本提供全面的診斷資訊。

進入新興市場：

由於醫療支出增加、疾病早期診斷意識增強以及醫療基礎設施發展等因素，免疫測定市場在新興國家正在擴大。儘管受到成本和監管障礙的限制，這種擴張為免疫測定儀器製造商開闢了新的前景。

Immunoassay Market size was valued at USD 27.53 Billion in 2023 and is projected to reach USD 39.66 Billion by 2031, growing at a CAGR of 4.67% from 2024 to 2031. An immunoassay is a laboratory technique that detects the presence or quantity of a material, usually a protein or other biomolecule, by analyzing its interaction with certain antibodies. To put it simply, antibodies are used to recognize and bind to the target molecule, allowing it to be identified or quantified. Immunoassays are widely used in a variety of disciplines, including medicine, biology, environmental science, and food safety. In medicine, they are commonly used to diagnose infectious diseases, monitor hormone levels, identify medications or poisons in the body, and test immunological responses to immunizations.

Additionally, they are used in agriculture to identify toxins in food, as well as in environmental monitoring to quantify pollutants in water and soil.

Global Immunoassay Market Dynamics

The key market dynamics that are shaping the immunoassay market include:

Key Market Drivers

Increased Prevalence of Chronic Diseases:

The increased global incidence of chronic diseases such as cancer, diabetes, and cardiovascular disorders needs early detection and monitoring, is driving the demand for immunoassays in clinical settings for accurate and speedy testing.

Advancements in Technology:

Continuous developments in immunoassay technology, including automation and high-throughput systems, have improved the tests' efficiency, sensitivity and specificity. This technological advancement enables improved illness identification and monitoring, bolstering the expansion of immunoassay market.

Growing Demand for Point-of-Care Testing:

The demand for quick, dependable, and simple diagnostic tests at point-of-care locations (such as clinics and home care) is growing. Immunoassays with quick findings are becoming vital tools in these settings, growing the market.

Expansion of Applications in Drug Development and Therapeutics:

Immunoassays are increasingly used in drug development and therapeutics, where they aid in drug discovery, pharmacokinetics, and toxicology research. The increasing investment in research and development activities in these industries drives up demand for immunoassays, accelerating market expansion.

Key Challenges:

High Cost of Advanced Immunoassay Systems:

The development and application of sophisticated immunoassay technologies are costly. This includes the cost of expensive equipment and reagents, which is a substantial impediment to smaller laboratories and healthcare organizations adopting these technologies, limiting market expansion.

Lack of Skilled Professionals:

Advanced immunoassay findings have to be operated on and interpreted by highly competent individuals. There is a dearth of educated workers, which inhibits the effective usage and acceptance of immunoassay technology, particularly in emerging regions, preventing market expansion.

Key Trends:

Integration of Artificial Intelligence (AI) and Machine Learning (ML):

Artificial intelligence and machine learning are rapidly being integrated into immunoassay platforms to improve data processing and interpretation. This integration enhances diagnosis accuracy, allows for predictive analytics, and streamlines laboratory procedures, extending the limitations of standard immunoassay applications.

Point-of-Care (POC) and Home-Based Testing:

There is a rising trend towards designing compact, user-friendly immunoassay tests for point-of-care and home use. This transition is being driven by the demand for quick, convenient testing choices that yield instant findings, decreasing the need for specialized laboratory facilities.

Multiplex Assays:

Multiplexing, which allows for the simultaneous testing of numerous analytes, is becoming increasingly popular. This trend is gaining popularity owing to high demand for high-throughput, efficient testing procedures that save time and costs while giving comprehensive diagnostic information from a single sample.

Expansion into Emerging Markets:

The immunoassay market is growing in emerging economies, driven by rising healthcare spending, increased awareness of early disease diagnosis, and the creation of healthcare infrastructure. Despite constraints such as cost sensitivity and regulatory hurdles, this expansion opens up new prospects for immunoassay suppliers.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Immunoassay Market Regional Analysis

Here is a more detailed regional analysis of the Immunoassay Market:

North America:

According to Verified Market Research, North America is estimated to dominate during the forecast period. North America, particularly the United States, has an advanced healthcare infrastructure with extensive access to cutting-edge medical technologies. This allows for rapid adoption and integration of immunoassays across a variety of healthcare settings, resulting in market growth.

The region has one of the world's highest healthcare expenditures, with major investments in R&D. This financial capability encourages the use of pricey immunoassay technology in diagnostics and research, hence boosting the market.

Many of the world's leading immunoassay and biotechnology companies are based in North America. These organizations are at the cutting edge of innovation, contributing to the region's market domination through ongoing product development and strategic alliances.

Furthermore, the increased prevalence of chronic diseases in North America needs early detection and monitoring, including cancer, diabetes, and cardiovascular disease. This has resulted in increased demand for immunoassay-based diagnostics, which is driving market expansion in this region.

Asia Pacific:

Asia Pacific is estimated to grow at the highest CAGR during the forecast period. Many Asia Pacific countries are making considerable investments in healthcare infrastructure, such as hospitals and research institutions. This growth enables the use of modern diagnostic technologies, such as immunoassays, to cater to a rising patient base.

This region's economies are growing, thereby, contributing to a rise in healthcare spending. Governments and the corporate sector are increasing their investments in healthcare, especially preventative care and diagnostics, driving up demand for immunoassay technologies.

The public in the Asia Pacific region is becoming more aware of the necessity of early disease identification and frequent health checkups. This trend is resulting in greater use of immunoassays for screening and monitoring a variety of disorders.

Furthermore, chronic disease prevalence is increasing in the Asia Pacific region, with diabetes, cancer, and cardiovascular disease being among the most common. This public health concern emphasizes the importance of efficient and accurate diagnostic tests, such as immunoassays, for effectively managing and controlling these illnesses.

Europe:

Europe's population is ageing, making it increasingly prone to chronic diseases that require regular monitoring and diagnostic tests. As a result, there is a growing demand for immunoassays to identify cardiovascular illnesses, cancer, and autoimmune disorders.

Most European countries have high healthcare standards, with significant public and private investment in healthcare systems. This funding commitment promotes the use of modern diagnostic technologies, such as immunoassays, throughout the region.

Furthermore, Europe is home to some of the world's best research institutes and biotechnology businesses, generating a robust R&D ecosystem. This strong scientific community drives constant innovation in immunoassay technology and the creation of new assays, both of which contribute to market growth.

Global Immunoassay Market Segmentation Analysis

The Immunoassay Market is segmented based on Product, Technology, Specimen, Application, End-User, And Geography.

Immunoassay Market, By Product

Reagents & Kits
ELISA Reagents & Kits
CLIA Reagents & Kits
IFA Reagents & Kits
Rapid Test Reagent & Kits
ELISpot Reagent & Kits
Western Blot Reagent & Kits
Other Reagents & Kits
Analyzers
Open Ended Systems
Closed Ended Systems

Based on Product, the market is segmented into Reagents & Kits and Analyzers. The reagents & kits segment is estimated to dominate the immunoassay market due to their broad use in a range of applications, including clinical diagnostics, research, and drug development. Reagents and kits are required for the execution of immunoassays and are used in greater numbers than analyzers, which are capital equipment with longer replacement cycles. The need for reagents and kits stems from the necessity for regular replenishment, the development of new tests, and the expansion of immunoassay applications in both healthcare and research contexts.

Immunoassay Market, By Technology

ELISA
Chemiluminescence Immunoassay (CLIA)
Immunofluorescence Assay (IFA)
Rapid Tests
ELISpot
Western Blotting
Other Technologies

Based on Technology, the immunoassay market is segmented into ELISA, CLIA, IFA, Rapid Tests, ELISpot, Western Blotting and Others. The ELISA segment is estimated to exhibit the highest growth in the market over the forecast period owing to its broad use in clinical and scientific contexts due to its specificity, sensitivity, and adaptability. This technique is well-known and has been well-validated for a variety of applications, including illness diagnosis, vaccine development, and quality control operations. Furthermore, ELISA kits are available for a wide range of targets, making them the preferred method for detecting and measuring proteins, hormones, antibodies, and antigens.

Immunoassay Market, By Specimen

Blood
Saliva
Urine
Other Specimens

Based on Specimen, the market is segmented into Blood, Saliva, Urine and Other Specimens. The blood specimen segment is estimated to lead this segment during the forecast period. This dominance is attributed to blood tests' rich diagnostic information, which makes them the preferred option for a wide range of disorders and conditions. Blood-based immunoassays are essential for detecting viral diseases, hormone imbalances, drug monitoring, and biomarkers for a variety of chronic and acute illnesses. Blood tests are widely used in clinical diagnostics due to their reliability, accuracy, and broad applicability, as well as standardized collection and processing techniques.

Immunoassay Market, By Application

Infectious Diseases
Endocrinology
Oncology
Bone & Mineral Disorders
Cardiology
Blood Screening
Autoimmune Disorders
Allergy Diagnostics
Toxicology
Newborn Screening
Other Applications

Based on Application, the market is segmented into Infectious Diseases, Endocrinology, Oncology, Bone & Mineral Disorders, Cardiology, Blood Screening, Autoimmune Disorders, Allergy Diagnostics, Toxicology, Newborn Screening and Other Applications. Infectious Disease is estimated to hold the majority share in the immunoassay market owing to the high global prevalence of infectious diseases such as HIV, TB, and hepatitis, as well as the increasing occurrence of new and emerging infections. The COVID-19 pandemic emphasized the importance of immunoassays in detecting infectious agents quickly and accurately, resulting in a considerable increase in demand for these tests.

Immunoassay Market, By End-User

Hospitals & Clinics
Clinical Laboratories
Pharmaceutical & Biotechnology
Blood Banks
Research & Academic Laboratories
Home Care Settings

Based on End-User, the market is segmented into Hospitals & Clinics, Clinical Laboratories, Pharmaceutical & Biotechnology, Blood Banks, Research & Academic Laboratories and Home Care Settings. The hospitals & clinics segment is estimated to show the highest growth in the forecasted period due to a wide range of services such as diagnostic testing, patient care, and illness treatment. Hospitals and clinics provide primary healthcare to the great majority of the population, allowing for disease detection, diagnosis, and treatment at an early stage. The large patient volume in these settings raises the demand for immunoassay tests, making them an essential component of patient care practices.

Immunoassay Market, By Geography

North America
Europe
Asia Pacific
South America
Middle East & Africa

Based on Geography, the immunoassay market is classified into North America, Europe, Asia Pacific, South America, and the Middle East & Africa. North American region is estimated to hold the largest share in the immunoassay market. North America, particularly the United States, has a highly developed healthcare system that allows for the rapid adoption and integration of new diagnostic technology, such as immunoassays. The region's significant investment in healthcare and R&D promotes innovation and the development of novel immunoassay techniques and platforms.

Key Players

The "Immunoassay Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Abbott Laboratories, Danaher Corporation, Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Johnson & Johnson, Meriden Life Sciences, Trinity Biotech plc, Mindray Medical International Limited, DiaSorin S.p.A., Hycel Ltd., Euroimmun AG, Stago Diagnostica, and Arkray.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Immunoassay Market Recent Developments
In February 2024, Abbott announced the FDA has approved the ARCHITECT Sepsis hTHP, a revolutionary AI-powered immunoassay that employs machine learning to detect sepsis faster and more precisely. This development has the potential to greatly enhance patient outcomes in this life-threatening illness.
In February 2024, Roche launched the Elecsys tau blood test, an immunoassay intended to aid in the early identification of Alzheimer's disease. This advancement shows hope for earlier intervention and better patient care in this progressive neurodegenerative disease.
In February 2024, Quidel collaborated with Merck to create and commercialize point-of-care immunoassays for infectious illnesses. This collaboration intends to provide faster and more accessible diagnostic options to patients in a variety of healthcare settings.